(Q33746152)

29 July 2017

1 reference

title

The pharmacology of bisphosphonates and new insights into their mechanisms of action (English)

1 reference

29 July 2017

1 reference

Russell RG

1

1 reference

29 July 2017

Rogers MJ

2

1 reference

29 July 2017

Frith JC

3

1 reference

29 July 2017

Luckman SP

4

1 reference

29 July 2017

Coxon FP

5

1 reference

29 July 2017

Benford HL

6

1 reference

29 July 2017

Croucher PI

7

1 reference

29 July 2017

Shipman C

8

1 reference

29 July 2017

Fleisch HA

9

1 reference

29 July 2017

language of work or name

1 reference

1 October 1999

1 reference

Journal of Bone and Mineral Research

29 July 2017

published in

1 reference

29 July 2017

volume

14 Suppl 2

1 reference

29 July 2017

page(s)

53-65

1 reference

Ueber die Einwirkung des Chloracetyls auf phosphorige Säure

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Diphosphonates and Page's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The management of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Overview of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Structure-activity relationships of various bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Adverse effects of bisphosphonates. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Regulation of osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Human osteoclast formation and activity in vitro: effects of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Rho GTPases and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Paramyxoviruses and Paget's disease: the affirmative view

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.5650140212

21 January 2018

Identifiers

DOI

10.1002/JBMR.5650140212

1 reference

29 July 2017

1 reference